Latest Company Intelligence

• Buy The First Trust Biotech Index Fund To Spread Risk And Build Wealth 
  Seeking Alpha  | Sep 14,'11
  Few sectors in the stock market can be as risky and rewarding as the biotechnology sector. Investors in this sector are banking on more than just corporate fundamentals to see a pay-off on their investment. Some companies have greatly rewarded investors, such as Biogen Idec ( BIIB ). Others have yet to see their best days, such as Human Genome Sciences ( HGSI ). And others have shocked
• Biogen Idec: Fairly Priced With A Healthy Balance Sheet 
  Seeking Alpha  | Sep 12,'11
  Biogen Idec Inc. ( BIIB ) is up about 58% over the past twelve months. The driving force is Biogen's promising MS drug candidate BG-12 with the belief that earnings can grow exponentially in the years ahead. If one company has a lock on the MS market, it is Biogen Idec. Shares are up nearly 67% at $90.24 from the 52-week low of $54.13. The consensus price target is $112.17 and
• INTERVIEW-Biogen CEO hopes Icahn board members will stay on 
  FOXBusiness.com  | Sep 12,'11
  BOSTON (Reuters) - The chief executive of Biogen Idec Inc said he wants members of the biotechnology company's board who were originally nominated by activist investor Carl Icahn to remain, even though Icahn has significantly reduced his stake in the company. "As far as I'm concerned they are really good board members and I'm really happy to have them," George Scangos, who took over as
• Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011) -- Additional Views from Chief Judge Rader 
  Patent Docs  | Sep 9,'11
  Accompanying the Federal Circuit's majority decision in Classen Immunotherapies, Inc. v. Biogen IDEC is a separate explication of "additional views" by Chief Judge Rader (at right) joined by Judge Newman. These views tend towards the policy and philosophical implications of patent eligibility challenges before the Court in several cases ( In re Bilski , Prometheus Laboratories, Inc. v.
• Top Analyst Upgrades & Downgrades (AMGN, ARIA, BIIB, CELG, LFC, CSCO, DRI, FIO, GPN, HUM, LEN, MSI, TLB, TZOO) 
  24/7 Wall St  | Sep 8,'11
  These are some of this Thursday's top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Outperform at BMO. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) Started as Outperform at BMO. Biogen Idec Inc. (NASDAQ: BIIB) Started as Underperform at BMO. Celgene Corporation (NASDAQ: CELG) Started as
• Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011) -- Judge Moore's Dissent 
  Patent Docs  | Sep 7,'11
  The Federal Circuit majority decision in Classen Immunotherapies, Inc. v. Biogen IDEC engendered a strong dissent from Judge Moore on almost every aspect of that decision. Judge Moore disagreed with the majority's opinion that the claims were patent-eligible, that the issue of inherent anticipation was not properly before the Court, and that certain activities by defendant

• To See More On FirstRain, Request A Trial >